We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+13.63%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.23B
AUM Growth
-$49.2M
Cap. Flow
-$49.5M
Cap. Flow %
-4.02%
Top 10 Hldgs %
42.54%
Holding
214
New
40
Increased
35
Reduced
19
Closed
53

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$30.3M
2
HROW icon
Harrow
HROW
+$15.8M
3
KOD icon
Kodiak Sciences
KOD
+$14.1M
4
CLDX icon
Celldex Therapeutics
CLDX
+$12.6M
5
BBIO icon
BridgeBio Pharma
BBIO
+$11.6M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$60.4M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$25.8M
3
RAPT
RAPT Therapeutics
RAPT
+$22.5M
4
ABVX
Abivax
ABVX
+$17.6M
5
AMGN icon
Amgen
AMGN
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 56.39%
2 Financials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
76
PUT
Arrowhead Research
ARWR
$10.5B
$3.61M 0.29%
+57,500
New +$3.64M
BHVN icon
77
Biohaven
BHVN
$2.32B
$3.49M 0.28%
412,481
+200,000
+94% +$2.19M
IVVD icon
78
Invivyd
IVVD
$219M
$3.45M 0.28%
2,656,570
– –
ELVN icon
79
PUT
Enliven Therapeutics
ELVN
$3.8B
$3.28M 0.27%
+83,700
New +$2.32M
ANNX icon
80
Annexon
ANNX
$950M
$3.21M 0.26%
580,244
+350,000
+152% +$1.97M
FBRX icon
81
Forte Biosciences
FBRX
$1B
$3.08M 0.25%
118,972
-181,028
-60% -$5.22M
LXEO icon
82
Lexeo Therapeutics
LXEO
$368M
$2.94M 0.24%
513,011
– –
VERA icon
83
CALL
Vera Therapeutics
VERA
$2.76B
$2.88M 0.23%
+71,700
New +$3.09M
PCSC
84
Perceptive Capital Solutions
PCSC
$123M
$2.64M 0.21%
240,951
– –
VIR icon
85
Vir Biotechnology
VIR
$1.59B
$2.63M 0.21%
293,258
-282,454
-49% -$2.25M
NXTC icon
86
NextCure
NXTC
$24.4M
$2.51M 0.2%
238,303
– –
NMRA icon
87
Neumora Therapeutics
NMRA
$298M
$2.49M 0.2%
1,278,408
– –
ABOS icon
88
Acumen Pharmaceuticals
ABOS
$163M
$2.49M 0.2%
1,053,797
+799,485
+314% +$2.04M
CABA icon
89
Cabaletta Bio
CABA
$461M
$2.42M 0.2%
900,000
– –
BBOT
90
BridgeBio Oncology
BBOT
$686M
$2.42M 0.2%
270,231
+50,000
+23% +$537K
PRQR icon
91
ProQR Therapeutics
PRQR
$240M
$2.42M 0.2%
1,492,229
– –
NUVL
92
DELISTED
Nuvalent
NUVL
$2.42M 0.2%
23,594
-36,000
-60% -$3.67M
AVTX icon
93
PUT
Avalo Therapeutics
AVTX
$1.02B
$2.37M 0.19%
+158,500
New +$2.48M
JAZZ icon
94
Jazz Pharmaceuticals
JAZZ
$15.5B
$2.36M 0.19%
12,460
-147,907
-92% -$25.8M
REPL icon
95
PUT
Replimune Group
REPL
$859M
$2.29M 0.19%
+300,000
New +$2.29M
DBVT
96
DBV Technologies
DBVT
$870M
$2.2M 0.18%
525,000
– –
TARS icon
97
Tarsus Pharmaceuticals
TARS
$2.61B
$2.19M 0.18%
31,166
– –
KLRS
98
Kalaris Therapeutics
KLRS
$104M
$2.08M 0.17%
360,000
– –
AVR
99
Anteris Technologies
AVR
$823M
$2.03M 0.17%
+366,571
New +$2.11M
SLDB icon
100
Solid Biosciences
SLDB
$858M
$1.9M 0.15%
264,409
+104,000
+65% +$668K
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CNAM
Campbell Newman Asset Management Milwaukee, Wisconsin $1.23B AUM 27.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.24B AUM 31.81% 1-Year Est. Return

Ikarian Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Ikarian Capital held 214 positions worth $1.23B, down 3.8% from $1.28B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital withdrew a net $49.5M in Q1 2026, closing 53 positions and reducing 19 holdings. Its most notable exit was Cidara Therapeutics, an estimated $60.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 60% a quarter earlier, followed by Financials.

Against the trend, Ikarian Capital opened a new position in Alumis Inc worth $26.7M.

  • Ikarian Capital's largest Q1 2026 buy was Alumis Inc: 1,213,548 shares worth $26.7M.
  • Ikarian Capital added most to Harrow in Q1 2026, an estimated $15.8M increase.
  • Ikarian Capital's biggest Q1 2026 reduction was Jazz Pharmaceuticals, cutting an estimated $25.8M.
  • Ikarian Capital fully exited Cidara Therapeutics in Q1 2026, selling an estimated $60.4M.
  • Ikarian Capital's ten largest holdings make up 43% of its $1.23B portfolio in Q1 2026.
  • Ikarian Capital opened 40 new positions and closed 53 in Q1 2026.
  • Ikarian Capital's portfolio value fell 3.8% quarter-over-quarter to $1.23B.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.